KRAS program (BeiGene)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameKRAS program (BeiGene)
Drug Alias Nametarget-2 (BeiGene)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New ZealandMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesBeOne Medicines Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeOne Medicines Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A